Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study

Takaaki Tokito, Oleksii Kolesnik, Jens Sørensen, Mehmet Artac, Martín Lázaro Quintela, Jong-Seok Lee, Maen Hussein, Miklos Pless, Luis Paz-Ares, Lance Leopold, Jeannie Daniel, Mihaela Munteanu, Ayman Samkari, Lu Xu, Charles Butts

Open source

DOI: 10.1186/s12885-023-11203-8
Published: 2024-07-25
Container: BMC Cancer
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-023-11203-8,
  title = {Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study},
  author = {Takaaki Tokito and Oleksii Kolesnik and Jens Sørensen and Mehmet Artac and Martín Lázaro Quintela and Jong-Seok Lee and Maen Hussein and Miklos Pless and Luis Paz-Ares and Lance Leopold and Jeannie Daniel and Mihaela Munteanu and Ayman Samkari and Lu Xu and Charles Butts},
  year = {2024},
  journal = {BMC Cancer},
  doi = {10.1186/s12885-023-11203-8},
  url = {https://doi.org/10.1186/s12885-023-11203-8}
}

RIS

TY  - JOUR
TI  - Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study
AU  - Takaaki Tokito
AU  - Oleksii Kolesnik
AU  - Jens Sørensen
AU  - Mehmet Artac
AU  - Martín Lázaro Quintela
AU  - Jong-Seok Lee
AU  - Maen Hussein
AU  - Miklos Pless
AU  - Luis Paz-Ares
AU  - Lance Leopold
AU  - Jeannie Daniel
AU  - Mihaela Munteanu
AU  - Ayman Samkari
AU  - Lu Xu
AU  - Charles Butts
PY  - 2024
JO  - BMC Cancer
DO  - 10.1186/s12885-023-11203-8
UR  - https://doi.org/10.1186/s12885-023-11203-8
ER  -

APA

Tokito, T., Kolesnik, O., Sørensen, J., Artac, M., Quintela, M. L., Lee, J., Hussein, M., Pless, M., Paz-Ares, L., Leopold, L., Daniel, J., Munteanu, M., Samkari, A., Xu, L., & Butts, C. (2024). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study. BMC Cancer. https://doi.org/10.1186/s12885-023-11203-8

Source records

crossref · retrieved 2026-09-26T17:39:50.402Z